OptimizeRx (OPRX) Interest Expenses (2010 - 2026)

OptimizeRx (OPRX) has 17 years of Interest Expenses data on file, last reported at $21.7 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 1574.79% year-over-year to $21.7 million; the trailing twelve-month figure through Mar 2026 stood at $21.7 million (up 267.42% YoY), and the FY2025 full-year result was $21.7 million, up 250.19% from the prior year.
• Interest Expenses grew to $21.7 million in Q1 2026, from $1.2 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $21.7 million in Q1 2026 to a low of $1236.0 in Q2 2023.
• A 5-year average of $3.1 million and a median of $1.5 million in 2024 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses plunged 91.83% in 2023 and soared 123524.6% in 2024, its largest moves.
• Tracing OPRX's Interest Expenses over 5 years: stood at $8.2 million in 2022, then sank by 91.83% to $667000.0 in 2023, then soared by 134.33% to $1.6 million in 2024, then dropped by 20.6% to $1.2 million in 2025, then jumped by 1650.36% to $21.7 million in 2026.
• Business Quant data shows OPRX's Interest Expenses at $21.7 million in Q1 2026, $1.2 million in Q4 2025, and $1.9 million in Q3 2025.